

Cognitive behavioral therapy (CBT) for schizophrenia/psychosis

Adult Mental Health: Serious Mental Illness

Benefit-cost estimates updated December 2023. Literature review updated December 2014.

Current estimates replace old estimates. Numbers will change over time as a result of model inputs and monetization methods.

The WSIPP benefit-cost analysis examines, on an apples-to-apples basis, the monetary value of programs or policies to determine whether the benefits from the program exceed its costs. WSIPP's research approach to identifying evidence-based programs and policies has three main steps. First, we determine "what works" (and what does not work) to improve outcomes using a statistical technique called meta-analysis. Second, we calculate whether the benefits of a program exceed its costs. Third, we estimate the risk of investing in a program by testing the sensitivity of our results. For more detail on our methods, see our [Technical Documentation](#).

Program Description: Cognitive behavioral therapy for psychosis (CBTp) includes the application of cognitive strategies focused on changing thoughts to improve feelings and behaviors as well as behavioral techniques most often used to address negative symptoms. CBTp involves teaching patients methods of coping with their symptoms and training in problem solving, social skills and strategies to reduce risk of relapse. In this collection of studies, CBTp was provided in addition to antipsychotic medication.

Benefit-Cost Summary Statistics Per Participant

Benefits to:

Taxpayers	\$9,566	Benefit to cost ratio	\$9.70
Participants	\$1,395	Benefits minus costs	\$14,930
Others	\$2,012	Chance the program will produce	
Indirect	\$3,671	benefits greater than the costs	60%
Total benefits	\$16,645		
Net program cost	(\$1,715)		
Benefits minus cost	\$14,930		

The estimates shown are present value, life cycle benefits and costs. All dollars are expressed in the base year chosen for this analysis (2022). The chance the benefits exceed the costs are derived from a Monte Carlo risk analysis. The details on this, as well as the economic discount rates and other relevant parameters are described in our [Technical Documentation](#).

Meta-Analysis of Program Effects

Outcomes measured	Treatment age	No. of effect sizes	Treatment N	Adjusted effect sizes and standard errors used in the benefit-cost analysis						Unadjusted effect size (random effects model)	
				First time ES is estimated			Second time ES is estimated			ES	p-value
				ES	SE	Age	ES	SE	Age		
Major depressive disorder	36	15	727	-0.123	0.070	37	-0.091	0.096	38	-0.123	0.078
Anxiety disorder	36	7	267	0.017	0.103	37	0.013	0.097	38	0.017	0.866
Global functioning [^]	36	18	721	0.231	0.069	37	n/a	n/a	n/a	0.232	0.001
Hospitalization (psychiatric)	36	16	832	-0.124	0.106	37	-0.092	0.122	38	-0.124	0.241
Psychiatric symptoms [^]	36	25	1172	-0.148	0.101	37	n/a	n/a	n/a	-0.148	0.144
Suicidal ideation [^]	36	2	115	-0.174	0.331	37	n/a	n/a	n/a	-0.174	0.599
Psychosis symptoms (positive) [^]	36	33	1477	-0.178	0.059	37	n/a	n/a	n/a	-0.178	0.003
Psychosis symptoms (negative) [^]	36	25	1143	-0.170	0.069	37	n/a	n/a	n/a	-0.170	0.014
Medication adherence [^]	36	2	75	-0.011	0.195	37	n/a	n/a	n/a	-0.011	0.956
Hope [^]	36	3	92	0.300	0.249	37	n/a	n/a	n/a	0.300	0.299

[^]WSIPP's benefit-cost model does not monetize this outcome.

Meta-analysis is a statistical method to combine the results from separate studies on a program, policy, or topic in order to estimate its effect on an outcome. WSIPP systematically evaluates all credible evaluations we can locate on each topic. The outcomes measured are the types of program impacts that were measured in the research literature (for example, crime or educational attainment). Treatment N represents the total number of individuals or units in the treatment group across the included studies.

An effect size (ES) is a standard metric that summarizes the degree to which a program or policy affects a measured outcome. If the effect size is positive, the outcome increases. If the effect size is negative, the outcome decreases.

Adjusted effect sizes are used to calculate the benefits from our benefit cost model. WSIPP may adjust effect sizes based on methodological characteristics of the study. For example, we may adjust effect sizes when a study has a weak research design or when the program developer is involved in the research. The magnitude of these adjustments varies depending on the topic area.

WSIPP may also adjust the second ES measurement. Research shows the magnitude of some effect sizes decrease over time. For those effect sizes, we estimate outcome-based adjustments which we apply between the first time ES is estimated and the second time ES is estimated. We also report the unadjusted effect size to show the effect sizes before any adjustments have been made. More details about these adjustments can be found in our [Technical Documentation](#).

Detailed Monetary Benefit Estimates Per Participant

Affected outcome:	Resulting benefits: ¹	Benefits accrue to:				
		Taxpayers	Participants	Others ²	Indirect ³	Total
Major depressive disorder	Labor market earnings associated with major depression	\$926	\$2,182	\$0	\$0	\$3,109
Anxiety disorder	Labor market earnings associated with anxiety disorder	(\$384)	(\$904)	\$0	\$0	(\$1,288)
Anxiety disorder	Health care associated with anxiety disorder	(\$26)	(\$7)	(\$26)	(\$13)	(\$72)
Hospitalization (psychiatric)	Health care associated with psychiatric hospitalization	\$9,049	\$123	\$2,038	\$4,524	\$15,734
Major depressive disorder	Mortality associated with depression	\$1	\$2	\$0	\$17	\$20
Program cost	Adjustment for deadweight cost of program	\$0	\$0	\$0	(\$858)	(\$858)
Totals		\$9,566	\$1,395	\$2,012	\$3,671	\$16,645

¹In addition to the outcomes measured in the meta-analysis table, WSIPP measures benefits and costs estimated from other outcomes associated with those reported in the evaluation literature. For example, empirical research demonstrates that high school graduation leads to reduced crime. These associated measures provide a more complete picture of the detailed costs and benefits of the program.

²"Others" includes benefits to people other than taxpayers and participants. Depending on the program, it could include reductions in crime victimization, the economic benefits from a more educated workforce, and the benefits from employer-paid health insurance.

³"Indirect benefits" includes estimates of the net changes in the value of a statistical life and net changes in the deadweight costs of taxation.


Detailed Annual Cost Estimates Per Participant

	Annual cost	Year dollars	Summary
Program costs	\$1,436	2014	Present value of net program costs (in 2022 dollars) (\$1,715)
Comparison costs	\$0	2014	Cost range (+ or -) 10%

Per-participant cost of treatment by modality (group/individual) was weighted by treatment Ns reported in the studies. Cost per-session per-person was \$37.91/session for group and \$120.90 for individual therapy (2014 dollars), based on actuarial tables reported for disabled adults in Mercer (2013) Behavioral Health Data Book for the State of Washington For Rates Effective January 1, 2014.


The figures shown are estimates of the costs to implement programs in Washington. The comparison group costs reflect either no treatment or treatment as usual, depending on how effect sizes were calculated in the meta-analysis. The cost range reported above reflects potential variation or uncertainty in the cost estimate; more detail can be found in our [Technical Documentation](#).

Benefits Minus Costs Over Time (Cumulative Discounted Dollars)




The graph above illustrates the estimated cumulative net benefits per-participant for the first fifty years beyond the initial investment in the program. We present these cash flows in discounted dollars. If the dollars are negative (bars below \$0 line), the cumulative benefits do not outweigh the cost of the program up to that point in time. The program breaks even when the dollars reach \$0. At this point, the total benefits to participants, taxpayers, and others, are equal to the cost of the program. If the dollars are above \$0, the benefits of the program exceed the initial investment.

Benefits by Perspective Over Time (Cumulative Discounted Dollars)



The graph above illustrates the breakdown of the estimated cumulative benefits (not including program costs) per-participant for the first fifty years beyond the initial investment in the program. These cash flows provide a breakdown of the classification of dollars over time into four perspectives: taxpayer, participant, others, and indirect. "Taxpayers" includes expected savings to government and expected increases in tax revenue. "Participants" includes expected increases in earnings and expenditures for items such as health care and college tuition. "Others" includes benefits to people other than taxpayers and participants. Depending on the program, it could include reductions in crime victimization, the economic benefits from a more educated workforce, and the benefits from employer-paid health insurance. "Indirect benefits" includes estimates of the changes in the value of a statistical life and changes in the deadweight costs of taxation. If a section of the bar is below the \$0 line, the program is creating a negative benefit, meaning a loss of value from that perspective.



The graph above focuses on the subset of estimated cumulative benefits that accrue to taxpayers. The cash flows are divided into the source of the value.

Citations Used in the Meta-Analysis

- Bach, P., & Hayes, S.C. (2002). The use of acceptance and commitment therapy to prevent the rehospitalization of psychotic patients: a randomized controlled trial. *Journal of Consulting and Clinical Psychology, 70*(5), 1129-39.
- Barrowclough, C., Haddock, G., Lobban, F., Jones, S., Siddle, R., Roberts, C., & Gregg, L. (2006). Group cognitive-behavioural therapy for schizophrenia: Randomised controlled trial. *The British Journal of Psychiatry, 189*, 6, 527-532.
- Bateman, K., Hansen, L., Turkington, D., & Kingdon, D. (2007). Cognitive Behavioral Therapy reduces suicidal ideation in schizophrenia: Results from a randomized controlled trial. *Suicide and Life-Threatening Behavior, 37*(3), 284-290.
- Bechdolf, A., Knost, B., Kuntermann, C., Schiller, S., Klosterkötter, J., Hambrecht, M., & Pukrop, R. (2004). A randomized comparison of group cognitive-behavioural therapy and group psychoeducation in patients with schizophrenia. *Acta Psychiatrica Scandinavica, 110*, 21-28.
- Bradshaw, W. (2000). Integrating cognitive-behavioral psychotherapy for persons with schizophrenia into a psychiatric rehabilitation program: results of a three year trial. *Community Mental Health Journal, 36*(5), 491-500.
- Cather, C., Penn, D., Otto, M.W., Yovel, I., Mueser, K.T., & Goff, D.C. (2005). A pilot study of functional Cognitive Behavioral Therapy (fCBT) for schizophrenia. *Schizophrenia Research, 74*, 2-3.
- Daniels, L. (1998). A group cognitive-behavioral and process-oriented approach to treating the social impairment and negative symptoms associated with chronic mental illness. *The Journal of Psychotherapy Practice and Research, 7*(2), 167-76.
- Durham, R.C., Guthrie, M., Morton, R.V., Reid, D.A., Treliving, L.R., Fowler, D., & Macdonald, R.R. (2003). Tayside-Fife clinical trial of cognitive-behavioural therapy for medication-resistant psychotic symptoms. Results to 3-month follow-up. *The British Journal of Psychiatry: the Journal of Mental Science, 182*, 303-11.
- Edwards, J., Cocks, J., Burnett, P., Maud, D., Wong, L., Yuen, H.P., Harrigan, S.M., ... McGorry, P D. (2011). Randomized controlled trial of clozapine and CBT for first-episode psychosis with enduring positive symptoms: A pilot study. *Schizophrenia Research and Treatment*.
- Farhall, J., Freeman, N.C., Sawyer, F., & Trauer, T. (2009). An effectiveness trial of cognitive behaviour therapy in a representative sample of outpatients with psychosis. *The British Journal of Clinical Psychology / the British Psychological Society, 48*, 47-62.
- Fowler, D., Hodgkins, J., Painter, M., Reilly, T., Crane, C., Macmillan, I., Muford, M., ... Jones, P.B. (2009). Cognitive behaviour therapy for improving social recovery in psychosis: a report from the ISREP MRC Trial Platform Study (Improving Social Recovery in Early Psychosis). *Psychological Medicine, 39*(10), 1627-36.

- Garety, P.A., Fowler, D.G., Freeman, D., Bebbinton, P., Dunn, G., & Kuipers, E. (2008). Cognitive-behavioural therapy and family intervention for relapse prevention and symptom reduction in psychosis: randomised controlled trial. *The British Journal of Psychiatry*, 192(6), 412-423.
- Gaudiano, B.A., & Herbert, J.D. (2006). Acute treatment of inpatients with psychotic symptoms using Acceptance and Commitment Therapy: Pilot results. *Behaviour Research and Therapy*, 44 (3), 415-437.
- Granholm, E., McQuaid, J.R., McClure, F.S., Link, P.C., Perivoliotis, D., Gottlieb, J.D., Patterson, T.L., ... Jeste, D. V. (2007). Randomized controlled trial of cognitive behavioral social skills training for older people with schizophrenia: 12-month follow-up. *The Journal of Clinical Psychiatry*, 68(5), 730-7.
- Granholm, E., Holden, J., Link, P.C., McQuaid, J.R., & Jeste, D.V. (2013). Randomized controlled trial of cognitive behavioral social skills training for older consumers with schizophrenia: Defeatist performance attitudes and functional outcome. *American Journal of Geriatric Psychiatry*, 21 (3), 251-262.
- Gumley, A.I., O'Grady, M., McNay, L., Reilly, J., Power, K.G., & Norrie, J. (2003). Early intervention for relapse in schizophrenia: results of a 12-month randomized controlled trial of cognitive behavioural therapy. *Psychological Medicine*, 33(3),419-431.
- Haddock, G., Tarrier, N., Morrison, A.P., Hopkins, R., Drake, R., & Lewis, S. (1999). A pilot study evaluating the effectiveness of individual inpatient cognitive-behavioural therapy in early psychosis. *Social Psychiatry and Psychiatric Epidemiology*, 34(5), 254-8.
- Haddock, G., Barrowclough, C., Shaw, J.J., Dunn, G., Novaco, R.W., & Tarrier, N. (2009). Cognitive-behavioural therapy v. social activity therapy for people with psychosis and a history of violence: randomised controlled trial. *The British Journal of Psychiatry : the Journal of Mental Science*, 194(2), 152-7.
- Jackson, H., McGorry, P., Edwards, J., Hulbert, C., Henry, L., Harrigan, S., Dudgeon, P., ... Power, P. (2005). A controlled trial of cognitively oriented psychotherapy for early psychosis (COPE) with four-year follow-up readmission data. *Psychological Medicine*, 35(9), 1295-306.
- Jackson, H.J., McGorry, P.D., Killackey, E., Bendall, S., Allott, K., Dudgeon, P., Gleeson, J., ... Harrigan, S. (2008). Acute-phase and 1-year follow-up results of a randomized controlled trial of CBT versus Befriending for first-episode psychosis: the ACE project. *Psychological Medicine*, 38(5), 725-35.
- Jolley, S., Garety, P., Craig, T., Dunn, G., White, J., & Aitken, M. (2003). Cognitive therapy in early psychosis: A pilot randomized controlled trial. *Behavioural and Cognitive Psychotherapy*, 31(4), 473-478.
- Kuipers, E., Garety, P., Fowler, D., & Dunn, G. (1997). London-East Anglia randomised controlled trial of cognitive-behavioural therapy for psychosis. I: Effects of the treatment phase. *The British Journal of Psychiatry*, 171, 319.
- Lecomte, T., Leclerc, C., Corbiere, M., Wykes, T., Wallace, C. J., & Spidel, A. (2008). Group cognitive behavior therapy or social skills training for individuals with a recent onset of psychosis? Results of a randomized controlled trial. *The Journal of Nervous and Mental Disease*, 196(12), 866-75.
- Levine, J., Barak, Y., & Granek, L. (1998). Cognitive Group Therapy for Paranoid Schizophrenics: Applying Cognitive Dissonance. *Journal of Cognitive Psychotherapy*, 12(1), 3.
- Lewis, D., Tarrier, N., Haddock, G., Bentall, R., Kinderman, P., Kingdon, D., Siddle, R., Drake, R., Everitt, J., ... Leadley K., (2002). Randomised controlled trial of cognitive-behavioural therapy in early schizophrenia: acute-phase outcomes. *British Journal of Psychiatry*, 181(Supplement), s91-s97.
- Lincoln, T.M., Ziegler, M., Mehl, S., Kesting, M.L., Lullmann, E., Westermann, S., & Rief, W. (2012). Moving from efficacy to effectiveness in cognitive behavioral therapy for psychosis: a randomized clinical practice trial. *Journal of Consulting and Clinical Psychology*, 80(4), 674-86.
- Moritz, S., Veckenstedt, R., Bohn, F., Hottenrott, B., Scheu, F., Randjbar, S., Aghotor, J., ... Roesch-Ely, D. (2013). Complementary group Metacognitive Training (MCT) reduces delusional ideation in schizophrenia. *Schizophrenia Research*, 151, 1-3.
- Peters, E., Landau, S., McCrone, P., Cooke, M., Evans, R., Carswell, K., ... Kuipers, E. (2010). A randomised controlled trial of cognitive behaviour therapy for psychosis in a routine clinical service. *Acta Psychiatrica Scandinavica*, 122 (4), 302-318.
- Pinninti, N.R., Rissmiller, D.J., & Steer, R.A. (2010). Cognitive-behavioral therapy as an adjunct to second-generation antipsychotics in the treatment of schizophrenia. *Psychiatric Services (Washington, D.C.)*, 61(9), 940-3.
- Pinto, A., La, P.S., Mennella, R., Giorgio, D., & DeSimone, L. (1999). Cognitive-behavioral therapy and clozapine for clients with treatment-refractory schizophrenia. *Psychiatric Services (Washington, D.C.)*, 50(7), 901-4.
- Rector, N.A., Seeman, M.V., & Segal, Z.V. (2003). Cognitive therapy for schizophrenia: a preliminary randomized controlled trial. *Schizophrenia Research*, 63, 1-2.
- Sensky, T., Turkington, D., Kingdon, D., Scott, J.L., Scott, J., Siddle, R., O'Carroll, M., ... Barnes, T.R. (2000). A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in schizophrenia resistant to medication. *Archives of General Psychiatry*, 57(2), 165-72.
- Startup, M., Jackson, M.C., & Bendix, S. (2004). North Wales randomized controlled trial of cognitive behaviour therapy for acute schizophrenia spectrum disorders: outcomes at 6 and 12 months. *Psychological Medicine*, 34(3), 413-22.
- Startup, M., Jackson, M.C., Evans, K.E., & Bendix, S. (2005). North Wales randomized controlled trial of cognitive behaviour therapy for acute schizophrenia spectrum disorders: two-year follow-up and economic evaluation. *Psychological Medicine*, 35(9), 1307-16.
- Tarrier, N., Beckett, R., Harwood, S., Baker, A., Yusupoff, L., & Ugarteburu, I. (1993). A trial of two cognitive-behavioural methods of treating drug-resistant residual psychotic symptoms in schizophrenic patients: I. Outcome. *The British Journal of Psychiatry : the Journal of Mental Science*, 162, 524-32.
- Tarrier, N., Wittkowski, A., Kinney, C., McCarthy, E., Morris, J., & Humphreys, L. (1999). Durability of the effects of cognitive-behavioural therapy in the treatment of chronic schizophrenia: 12-month follow-up. *The British Journal of Psychiatry*, 174(6), 500-504.
- Tarrier, N., Haddock, G., Lewis, S., Drake, R., & Gregg, L. (2006). Suicide behaviour over 18 months in recent onset schizophrenic patients: The effects of CBT. *Schizophrenia Research*, 83(1), 15-27.
- Trower, P., Birchwood, M., Meaden, A., Byrne, S., Nelson, A., & Ross, K. (2004). Cognitive therapy for command hallucinations: randomised controlled trial. *The British Journal of Psychiatry*, 184(4), 312-320.
- Turkington, D., & Kingdon, D. (2000). Cognitive-behavioural techniques for general psychiatrists in the management of patients with psychoses. *The British Journal of Psychiatry : the Journal of Mental Science*, 177, 101-6.
- Turkington, D., Kingdon, D., Turner, T., & Insight into Schizophrenia Research Group. (2002). Effectiveness of a brief cognitive-behavioural therapy intervention in the treatment of schizophrenia. *The British Journal of Psychiatry : the Journal of Mental Science*, 180, 523-7.
- Turkington, D., Kingdon, D., Rathod, S., Hammond, K., Pelton, J., & Mehta, R. (2006). Outcomes of an effectiveness trial of cognitive-behavioural intervention by mental health nurses in schizophrenia. *The British Journal of Psychiatry*, 189(1), 36-40.
- Valmaggia, L.R., van der Gaag, M., Tarrier, N., Pijnenborg, M., & Slooff, C.J. (2005). Cognitive-behavioural therapy for refractory psychotic symptoms of schizophrenia resistant to atypical antipsychotic medication: Randomised controlled trial. *The British Journal of Psychiatry*, 186(4), 324-330.
- van der Gaag, M., Stant, A.D., Wolters, K.J., Buskens, E., & Wiersma, D. (2011). Cognitive-behavioural therapy for persistent and recurrent psychosis in people with schizophrenia-spectrum disorder: cost-effectiveness analysis. *The British Journal of Psychiatry : the Journal of Mental Science*, 198(1), 59-65.
- White, R., Gumley, A., McTaggart, J., Rattrie, L., McConville, D., Cleare, S., & Mitchell, G. (2011). A feasibility study of Acceptance and Commitment Therapy for emotional dysfunction following psychosis. *Behaviour Research and Therapy*, 49(12), 901-907.

Wykes, T., Hayward, P., Thomas, N., Green, N., Surguladze, S., Fannon, D., & Landau, S. (2005). What are the effects of group cognitive behaviour therapy for voices? A randomised control trial. *Schizophrenia Research*, 77, 2-3.

For further information, contact:
(360) 664-9800, institute@wsipp.wa.gov

Printed on 03-22-2024



Washington State Institute for Public Policy

The Washington State Legislature created the Washington State Institute for Public Policy in 1983. A Board of Directors—representing the legislature, the governor, and public universities—governs WSIPP and guides the development of all activities. WSIPP's mission is to carry out practical research, at legislative direction, on issues of importance to Washington State.